Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 5Phase EARLY_PHASE1 3Phase 3 3Phase NA 2Phase 4 1Phase 1/2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 9Squamous Cell Carcinoma of Head and Neck 3Skin Neoplasms 3Sarcoma 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Sarcoma, Kaposi 1Pinealoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Muscle Invasive Bladder Urothelial Carcinoma 1Motor Activity 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lymphoid Interstitial Pneumonia 1Liver Neoplasms 1Laryngeal Diseases 1Hodgkin Disease 1Glioma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoma, Basal Cell 1Borderline Resectable Pancreatic Adenocarcinoma 1Acquired Immunodeficiency Syndrome 1

Interventions

Nivolumab 3Niacinamide 2HhAntag691 2urelumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1encorafenib 1cemiplimab 1binimetinib 1avelumab 1aldesleukin 1X-Rays 1Vitamin A 1Tranexamic Acid 1Sunscreening Agents 1Niacin 1Mohs Surgery 1Itraconazole 1Ipilimumab 1Interleukin-2 1Influenza Vaccines 1Indocyanine Green 1Immune Checkpoint Inhibitors 1Exercise 1Dimethyl Sulfoxide 1Cyclophosphamide 1Biopsy 1Ascorbic Acid 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Skin Neoplasms × Nivolumab × Clear all
NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
14 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
11 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡